ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,170.62
0.29%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,316.75
-0.70%
Brent Oil
82.275
0.18%
Bitcoin
66,184.61
-0.68%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Indaptus Therapeutics Inc (INDP)

  7. Indaptus Therapeutics Inc (INDP) News

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:INDP
DateTimeSourceHeadlineSymbolCompany
11/06/202413:00GlobeNewswire Inc.Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies SummitNASDAQ:INDPIndaptus Therapeutics Inc
07/06/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
07/06/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
04/06/202413:00GlobeNewswire Inc.Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
03/06/202413:00GlobeNewswire Inc.Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
30/05/202413:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
29/05/202413:00GlobeNewswire Inc.Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
22/05/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
22/05/202413:00GlobeNewswire Inc.Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsNASDAQ:INDPIndaptus Therapeutics Inc
08/05/202413:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
08/05/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
08/05/202413:00GlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
11/04/202412:30GlobeNewswire Inc.Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
28/03/202412:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
25/03/202412:30GlobeNewswire Inc.Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
18/03/202412:00GlobeNewswire Inc.Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024NASDAQ:INDPIndaptus Therapeutics Inc
13/03/202411:30GlobeNewswire Inc.Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
04/03/202416:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
04/03/202412:30GlobeNewswire Inc.Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortNASDAQ:INDPIndaptus Therapeutics Inc
15/02/202413:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
08/02/202413:00GlobeNewswire Inc.Indaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsNASDAQ:INDPIndaptus Therapeutics Inc
23/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
23/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
04/01/202413:00GlobeNewswire Inc.European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202321:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
06/11/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202321:01GlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202313:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202313:00GlobeNewswire Inc.Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNASDAQ:INDPIndaptus Therapeutics Inc
31/10/202313:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:INDP

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
LBE
Longboat Energy
LSE
GKP
Gulf Keystone Petroleum
LSE
SDRY
Superdry
LSE
TERN
Tern
LSE
RKH
Rockhopper Exploration
LSE
HE1
Helium One Global
LSE
EEE
Empire Metals
LSE
PANR
Pantheon Resources
LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
ENET
Ethernity Networks
LSE
KEFI
Kefi Gold And Copper
LSE
LONG
Longships
LSE
SOLG
Solgold
LSE
BIRD
Blackbird
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved